Sir Christopher Gent, chairman of Reform, the independent think-tank, let slip about his health when expounding policy for choice in healthcare last week. When challenged by a diabetic claiming that choice did not work, Gent responded: "As someone who could well be going down the same road as you…".
A musical mobile phone in the audience interrupted the former Vodafone boss, but as Gent is now chairman of GlaxoSmithKline, should we expect to see R&D diverted to this problem?
